Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinod K Rustgi

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Journal of Clinical Gastroenterology|October 9, 2010
Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trialFurqaan Ahmed, Ira M Jacobson, Jorge L Herrera, et al.
Annals of Hepatology|May 7, 2024
Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASHAnkoor H Patel, Gaurav N Pathak, Alexander Chen, et al.
Hepatology (Baltimore, Md.)|June 10, 2008
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeksMorris Sherman, Cihan Yurdaydin, Halis Simsek, et al.
Cancer Medicine|March 17, 2026
Impacts of Neighborhood Persistent Poverty and Socioeconomic Status on Hepatocellular Carcinoma Outcomes: A Large Population-Based Cohort StudyMohamed I Elsaid, Holli A Loomans-Kropp, Yesung Kweon, et al.
Hepatology (Baltimore, Md.)|February 1, 2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral loadStuart C Gordon, Zahary Krastev, Andrzej Horban, et al.
Gastroenterology|April 27, 2017
Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work GroupFasiha Kanwal, Bruce R Bacon, Lauren A Beste, et al.
Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2014
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)Scott Fung, Stuart C Gordon, Zahary Krastev, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Journal of Clinical Gastroenterology|October 9, 2010
Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trialFurqaan Ahmed, Ira M Jacobson, Jorge L Herrera, et al.
Annals of Hepatology|May 7, 2024
Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASHAnkoor H Patel, Gaurav N Pathak, Alexander Chen, et al.
Hepatology (Baltimore, Md.)|June 10, 2008
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeksMorris Sherman, Cihan Yurdaydin, Halis Simsek, et al.
Cancer Medicine|March 17, 2026
Impacts of Neighborhood Persistent Poverty and Socioeconomic Status on Hepatocellular Carcinoma Outcomes: A Large Population-Based Cohort StudyMohamed I Elsaid, Holli A Loomans-Kropp, Yesung Kweon, et al.
Hepatology (Baltimore, Md.)|February 1, 2013
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral loadStuart C Gordon, Zahary Krastev, Andrzej Horban, et al.
Gastroenterology|April 27, 2017
Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work GroupFasiha Kanwal, Bruce R Bacon, Lauren A Beste, et al.
Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2014
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)Scott Fung, Stuart C Gordon, Zahary Krastev, et al.
Pageof 8